NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Meeting Updates
Neuland Laboratories Limited has informed the Exchange about Earnings Call Details for Q4 FY 2021-202205-05-2022
05-05-2022
NEULAND LABORATORIES LTD. - 524558 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company NEULAND LABORATORIES LTD. 2 CIN NO. L85195TG1984PLC004393 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* NA 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) NA 8Quantum of (d), which has been met from (c)(e)* NA 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* NA Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)NA Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Sarada BhamidipatiDesignation :-Company Secretary Name of the Chief Financial Officer :- Deepak Gupta Designation : -Chief Financial Officer Date: 25/04/202225-04-2022
NEULAND LABORATORIES LTD. - 524558 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayNEULAND LABORATORIES LTD. 2CINL85195TG1984PLC004393 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 112.78 4Highest Credit Rating during the previous FY A- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INDIA RATINGS AND RESEARCH PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Sarada Bhamidipati Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Deepak Gupta Designation: Chief Financial Officer EmailId: [email protected] Date: 22/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.22-04-2022
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Credit Rating
Announcement under Regulation 30 (LODR)-Credit Rating21-04-2022
NEULAND LABORATORIES LTD. - 524558 - Compliances- Certificate Under Regulation 40(10) Of SEBI(LODR) Regulations, 2015
Compliances- Certificate Under Regulation 40(10) Of SEBI(LODR) Regulations, 201520-04-2022
NEULAND LABORATORIES LTD. - 524558 - Board Meeting Intimation for Considering And Approving The Audited Financial Results For The Quarter And Year Ended March 31, 2022 And To Recommend Final Dividend For FY 2021-22, If Any
NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2022 ,inter alia, to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2022 and to recommend final dividend for FY 2021-22, If any18-04-2022
NEULAND LABORATORIES LTD. - 524558 - Compliance Certificate- Regulation 7(3) Of SEBI(LODR) Regulations, 2015, For The Year Ended March 31, 2022
Compliance Certificate- Regulation 7(3) Of SEBI(LODR) Regulations, 2015, For The Year Ended March 31, 202213-04-2022
NEULAND LABORATORIES LTD. - 524558 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 202211-04-2022
NEULAND LABORATORIES LTD. - 524558 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on April 01, 2022 for Dr. Davuluri Rama Mohan Rao01-04-2022